Categories Earnings, Health Care

Medtronic (MDT) beats Q3 earnings estimates; revenues miss mark

Medtronic plc (NYSE: MDT) topped earnings expectations for the third quarter of 2020 while revenue fell short of estimates. The stock was down 2.8% in premarket hours on Tuesday.

Total revenue of $7.71 billion rose 2.3% from the same period a year ago but came below forecasts of $7.81 billion. On an organic basis, revenues grew 2.6%.

Medtronic (MDT) reports Q3 2020 earnings results

GAAP net income was $1.91 billion, or $1.42 per share. Adjusted net income grew over 11% to $1.94 billion, or $1.44 per share, beating projections of $1.38.  

For fiscal year 2020, adjusted EPS is expected to be $5.63-5.65. For the fourth quarter of 2020, adjusted EPS is expected to be $1.62-1.64.

In the third quarter, revenue in the US inched up 0.5% on a reported basis. Revenues in the non-US developed market rose 0.4% while emerging markets revenue climbed 12%.

Also read: Acasti Pharma Q3 2020 Earnings Snapshot

Revenues in the Cardiac and Vascular Group increased 1.2% during the quarter but the growth was lower than expected as customers refrained from making purchases ahead of new product launches in the Coronary & Structural Heart division. The company also saw a slower-than-expected recovery in left ventricular assist devices.  

Revenues in the Minimally Invasive Therapies Group grew 2.4%, driven by increases in the Surgical Innovations, and Respiratory, Gastrointestinal & Renal divisions. Revenue results in the segment were impacted by an upgrade to its enterprise resource planning system in the US and Canada.  

Revenues in the Restorative Therapies Group rose 4.2%, aided by growth in the Brain Therapies, Spine, and Specialty Therapies divisions. The results were slightly offset by a 3.5% decrease in revenue from Pain Therapies. Revenues in the Diabetes Group remained flat.   

During the quarter, Medtronic acquired software company Klue, whose behavior-tracking technology is expected to help in diabetes management by automating insulin delivery through the monitoring of patients’ eating habits.

Last month, the company acquired Stimgenics, the pioneer of a novel spinal cord stimulation waveform known as Differential Target Multiplexed Spinal Cord Stimulation, which is considered a unique option to treat patients with chronic pain. Both deals are expected to be neutral to FY2020 EPS.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

HPE Earnings: Hewlett Packard Q1 2024 profit drops but beats Street view

Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) on Thursday reported lower earnings and revenues for the first quarter of 2024. Earnings, however, exceeded analysts’ forecasts. First-quarter profit, excluding

After entering FY24 on a high note, Costco is all set to report Q2 results

Costco Wholesale Corporation (NASDAQ: COST) stands out in the retail space for its unique business model that enables the warehouse behemoth to grow store traffic and market share constantly. Currently,

Hormel (HRL) expects continued momentum from its foodservice business in FY2024

Shares of Hormel Foods Corporation (NYSE: HRL) soared over 13% on Thursday after the company delivered better-than-expected earnings results for the first quarter of 2024 and reaffirmed its outlook for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top